Agios Pharmaceuticals Management
Management criteria checks 4/4
Agios Pharmaceuticals' CEO is Brian Goff, appointed in Aug 2022, has a tenure of 2.5 years. total yearly compensation is $3.42M, comprised of 23.4% salary and 76.6% bonuses, including company stock and options. directly owns 0.14% of the company’s shares, worth $2.71M. The average tenure of the management team and the board of directors is 3.1 years and 7.8 years respectively.
Key information
Brian Goff
Chief executive officer
US$3.4m
Total compensation
| CEO salary percentage | 23.4% |
| CEO tenure | 2.5yrs |
| CEO ownership | 0.1% |
| Management average tenure | 3.1yrs |
| Board average tenure | 7.8yrs |
Recent management updates
Recent updates
Agios Pharmaceuticals: Considering Risk/Reward Ahead Of FDA Decision
Jan 14Agios Pharmaceuticals: A Long Overdue Follow Up
Dec 03We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate
Sep 26
Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment
Aug 27Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Aug 04Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline
Jun 12Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth
Jun 02Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates
Feb 17Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation
Jan 16Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 50%
Nov 09Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation
Sep 26Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?
May 08We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely
Feb 06Agios Pharmaceuticals (NASDAQ:AGIO) Is In A Good Position To Deliver On Growth Plans
Oct 18Agios Pyrukynd for rare blood disorder gets EMA panel backing for approval in EU
Sep 16Agios adds more than 13% after Novo deal to acquire rival Forma
Sep 01Agios Pharmaceuticals GAAP EPS of -$1.68 beats by $0.07
Aug 04Agios Pharmaceuticals Is A Buy On Coming Revenue Ramp
Jul 26Agios Pharmaceuticals appoints new board chair, CEO
Jul 12Agios: Approved Product, Upcoming Catalysts
May 10Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?
May 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$674m |
| Jun 30 2024 | n/a | n/a | -US$365m |
| Mar 31 2024 | n/a | n/a | -US$353m |
| Dec 31 2023 | US$3m | US$798k | -US$352m |
| Sep 30 2023 | n/a | n/a | -US$220m |
| Jun 30 2023 | n/a | n/a | -US$210m |
| Mar 31 2023 | n/a | n/a | -US$218m |
| Dec 31 2022 | US$12m | US$308k | -US$232m |
Compensation vs Market: Brian's total compensation ($USD3.42M) is below average for companies of similar size in the US market ($USD5.36M).
Compensation vs Earnings: Brian's compensation has been consistent with company performance over the past year.
CEO
Brian Goff (55 yo)
2.5yrs
Tenure
US$3,416,453
Compensation
Mr. Brian M. Goff, M.B.A., is Independent Director of Intellia Therapeutics, Inc. since June 2024. He is Chief Executive Officer and Director at Agios Pharmaceuticals, Inc. since August 08, 2022. He had be...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.5yrs | US$3.42m | 0.14% $ 2.7m | |
| Chief Financial Officer | 2.4yrs | US$1.21m | 0.035% $ 693.1k | |
| Corporate Secretary & Chief Legal Officer | 3.1yrs | US$1.93m | 0.028% $ 539.8k | |
| Chief Medical Officer and Head of Research & Development | 3.4yrs | US$2.87m | 0.077% $ 1.5m | |
| Chief Commercial Officer | 2.1yrs | US$3.73m | 0.033% $ 650.0k | |
| Founder | no data | US$333.51k | no data | |
| Founder | no data | no data | no data | |
| Founder | no data | no data | no data | |
| Founder | no data | no data | no data | |
| VP, Controller & Principal Accounting Officer | 3.5yrs | no data | 0.0014% $ 28.0k | |
| Chief Technical Operations Officer | 7.7yrs | no data | no data | |
| Vice President of Investor Relations & Corporate Communications | no data | no data | no data |
3.1yrs
Average Tenure
55yo
Average Age
Experienced Management: AGIO's management team is considered experienced (3.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.5yrs | US$3.42m | 0.14% $ 2.7m | |
| Chair of the Board of Directors | 7.2yrs | US$447.25k | 0.25% $ 4.8m | |
| Independent Director | 1.7yrs | US$663.68k | 0.0035% $ 67.8k | |
| Member of Scientific Advisory Board | 8.5yrs | US$302.85k | no data | |
| Member of Scientific Advisory Board | 16yrs | no data | no data | |
| Lead Independent Director | 10.2yrs | US$440.95k | 0.013% $ 259.6k | |
| Independent Director | 15.5yrs | US$417.25k | 0.83% $ 16.4m | |
| Independent Director | 9.7yrs | US$424.75k | 0.026% $ 512.7k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.5yrs | US$419.91k | 0.014% $ 274.7k | |
| Independent Director | 2.5yrs | US$427.25k | 0.014% $ 274.7k | |
| Independent Director | 7.8yrs | US$429.75k | 0.027% $ 532.3k |
7.8yrs
Average Tenure
64yo
Average Age
Experienced Board: AGIO's board of directors are considered experienced (7.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 22:53 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Agios Pharmaceuticals, Inc. is covered by 31 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| George Farmer | BMO Capital Markets Equity Research |
| Alec Stranahan | BofA Global Research |